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Abstract  
Detection of incipient Alzheimer disease (AD) pathophysiology is critical to identify preclinical 
individuals and target potentially disease-modifying therapies towards them. Current neuroimaging 
and biomarker research is strongly focused in this direction, with the aim of establishing AD 
fingerprints to identify individuals at high risk of developing this disease. By contrast, cognitive 
fingerprints for incipient AD are virtually nonexistent as diagnostics and outcomes measures are still 
focused on episodic memory deficits as the gold standard for AD, despite their low sensitivity and 
specificity for identifying at-risk individuals. This Review highlights a novel feature of cognitive 
evaluation for incipient AD by focusing on spatial navigation and orientation deficits, which are 
increasingly shown to be present in at-risk individuals. Importantly, the navigation system in the brain 
overlaps substantially with the regions affected by AD in both animal models and humans. Notably, 
spatial navigation has fewer verbal, cultural and educational biases than current cognitive tests, and 
could enable a more uniform, global approach towards cognitive fingerprints of AD and better 
cognitive treatment outcome measures in future multicentre trials. The current Review appraises the 
available evidence for spatial navigation and/or orientation deficits in preclinical, prodromal and 
confirmed AD, as well as identifying research gaps and future research priorities. 
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[H1] Introduction 
Alzheimer disease (AD) is the most common form of dementia, with increasing worldwide 
prevalence1,2. Accurate early diagnosis is crucial as it provides the chance to intervene at an early 
stage before substantial neuronal death occurs. This approach is particularly relevant in an era in 
which research is focused on the efficacy of upcoming pharmacological3–5 and non-pharmacological 
prevention and treatment strategies6, which might allow intervention when neuronal loss is at its 
minimum to stop or delay the progress of the pathophysiology.  
 
Current ‘gold standard’ clinical diagnostic and outcome measures for AD are strongly focused on 
episodic memory7. Episodic memory loss is one of the most common features of AD and is 
considered the most sensitive and specific cognitive marker of underlying AD pathophysiology8. 
However, it is becoming increasingly clear that decline in memory is so common in healthy ageing 
that early detection of incipient AD pathophysiology is difficult9, which in turn often delays diagnosis 
as clinicians schedule follow-up appointments in an attempt to confirm a progressive decline in 
memory performance. The situation is further complicated by the fact that other brain diseases,10–12 
such as frontotemporal dementia (FTD), can manifest with substantial memory deficits, despite 
having a different underlying pathology13.  
 
Given this limited specificity of episodic memory deficits for incipient underlying AD 
pathophysiology, a new approach is required. Emerging data reveals that spatial navigation and 
orientation deficits have higher specificity than episodic memory in distinguishing AD from other 
dementias, particularly FTD14,15. More specifically, in animal studies AD pathophysiology has been 
shown to affect navigation-specific brain areas before episodic memory areas are affected16. Further, 
healthy older adults do not experience topographical disorientation in well-known environments, 
which contrasts starkly with the spatial disorientation seen in early AD1718. Finally, analysis of spatial 
performance allows better translation of animal intervention studies to human clinical trials as 
conceptualization of episodic memory is difficult to apply to nonhuman species19. Despite these 
highly promising findings, the utility of such spatial navigation deficits for diagnosis in preclinical 
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individuals with a high genetic risk of AD or with mild cognitive impairment (MCI) [G] remains 
underexplored20,21. The current Review appraises the available evidence for spatial navigation deficits 
in preclinical, prodromal and confirmed AD, as well as identifying research gaps and future research 
priorities. 
 
[H1] AD diagnosis and criteria 
[H3] Diagnostic criteria 
According to the National Institute on Aging (2011), AD diagnostic criteria include a history of 
worsening amnestic and nonamnestic symptoms in the visuospatial, language and executive function 
domains that reflect the amyloid-β (Aβ) burden and neurodegeneration in the brain22. Positive test 
results for cerebrospinal fluid (CSF) biomarkers and PET amyloid imaging increase confidence in the 
clinical diagnosis and predict AD progression from prodromal stages23. Importantly, Aβ plaque 
deposition has been observed in post-mortem evaluations of individuals who were not judged to be 
symptomatic in their lifetime24,25, highlighting the complexity of the underlying AD pathology and 
time lag to clinical manifestation . A further complication is that biomarkers are not brain region-
specific, and do not equate to clinical outcomes or have real-life symptom relevance for patients26,27. 
Thus, the role of cognitive evaluations is important in the early diagnostic process and has great 
potential to complement established biomarkers. Given that the amnestic syndrome continues to 
appear as a ‘core’ criterion to support diagnosis of the most typical form of AD, we discuss the issues 
surrounding the use of memory tests in clinical settings below (for atypical AD see elsewhere28).  
 
[H3] Neuropathology over the lifetime  
At a biological level, AD clinical symptoms are associated with the accumulation of extracellular Aβ 
plaques and intracellular tau tangles, leading to neuronal apoptosis. The extracellular deposition of Aβ 
plaques usually occurs first in prefrontal brain regions but becomes widespread over the cortex even 
in healthy ageing. By contrast, the intraneuronal neurofibrillary tangles of tau protein show a highly 
specific spreading pattern through the brain in AD29. Typically, tangles first develop in the most 
superficial cellular layer of the transentorhinal cortex (Braak & Del Tredici Stage I) advancing to the 
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entorhinal cortex and Ammon's horn in the hippocampus (Stage II), later spreading to the amygdala, 
the anterodorsal thalamic nucleus and the rest of the hippocampal formation (Stage III). Finally, tau 
tangles continue to spread to neighbouring regions within the cerebral cortex causing neocortical 
atrophy23 (Stages IV–VI). The interaction of Aβ and tau leads to progressive neuronal loss, which in 
turn is believed to underlie AD symptomology, such as forgetfulness, disorientation and confusion28. 
The reason for the pronounced directional expansion of the tau pathological process in typical AD as 
well as the tau– Aβ interplay is still unknown. 
 
[H3] Limitations of episodic memory for AD diagnosis 
Given that patients with AD present with profound symptoms of forgetfulness and substantial Aβ load 
in the medial temporal lobe (MTL), it is not surprising that episodic memory is currently the gold 
standard for diagnosing probable AD7. Indeed, patients with substantial memory problems are highly 
likely to have underlying AD pathology. However, the reliance on episodic memory deficits for 
diagnosis in the prodromal or even preclinical stages is problematic, because episodic memory peaks 
in very early adulthood30 and progressively declines with normal ageing. Indeed, diagnosis can be 
challenging in people >75 years of age, in whom memory and associated MTL structures show 
considerable age-related changes not due to pathophysiological processes31. As a result, cognitive 
decline in  healthy older people >75 years might have been considerably underestimated by 
longitudinal studies32. Moreover, delayed recall ability, one of the current main cognitive diagnostic 
indicators of AD, progressively declines in healthy adults aged ≥65 years33, highlighting the potential 
difficulties with the sensitivity of episodic memory to diagnose and predict AD pathophysiology in an 
older population. Similarly, as mentioned above, it is becoming increasingly recognised that patients 
with other forms of dementia can also show significant episodic memory problems. For example, 
FTD subtypes — such as the behavioural variant of FTD (bvFTD) — often manifest with similar 
deficits of episodic memory as AD, even for pathologically confirmed cases of bvFTD12,34–36, which 
can make the differential diagnosis difficult9,13,15,37. Differential diagnosis is important when 
determining the underlying pathology and choosing the correct treatment strategy to manage 
symptoms. An early and differential diagnosis is particularly problematic for patients with AD who 
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exhibit neuropsychiatric symptoms, who can be very difficult to clinically distinguish from patients 
with bvFTD37. 
 
Unlike episodic memory impairments, spatial navigation or orientation problems are rarely reported in 
healthy older adults38 or non-AD dementias, and experimental studies have shown that spatial 
navigational paradigms that are independent of mnemonic process can differentiate patients with AD 
from individuals with other dementias and healthy control groups14,39. This finding is not surprising 
given that the neuropathology of AD starts in the entorhinal areas, which are crucial for successful 
navigation16,40–43. This evidence raises the question as to whether such symptoms might be more 
sensitive and specific to underlying AD pathophysiology, even at a preclinical (that is, pre-memory 
symptom onset) stage. In the following sections, we briefly introduce current knowledge of navigation 
strategies and their neural correlates before reviewing the evidence in normal ageing and AD.  
 
[H1] Spatial navigation 
[H3] Navigation strategies  
Spatial navigation is the process of determining and maintaining a trajectory between different points 
in our environment. Successful navigation relies on two co-dependent strategies: allocentric and 
egocentric navigation. These strategies use different types of spatial reference frames but are highly 
correlated44 (Figure 1). 
 
Egocentric strategies [G]  are generally used when the same route is followed over and over again45,46. 
These self-centred navigation frames encode spatial information from the viewpoint of the person 
navigating to form an internal representation that is based on a sequence of bodily movements. This 
sequence of movements allows the navigator to maintain their route-goal trajectory relatively free of 
conscious control. Perceptual processing is required, as available visual input, bodily distance from 
landmarks, sensorimotor and vestibular knowledge about position in space and self-motion are all 
utilised as navigational cues. The temporal order in which environmental stimuli are encountered is 
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important and facilitates the landmark-based behavioural responses that are stored in spatial memory 
(for example, turn left at a supermarket and right at the lights).  
 
On the other hand, when traveling a lesser known or novel route, spatial representations of sequential 
bodily movements are not available, and allocentric, world-centred strategies are employed instead. 
Allocentric strategies [G] are based on the navigator’s perception of landmark positions relative to 
other landmarks. These positions are memorised and estimated by the navigator, contributing to an 
internal representation or ‘cognitive map’ that enables an individual to plan shorter routes regardless 
of their starting point46,47. Allocentric representations of self-location are updated by self-motion on 
the basis of visual, auditory, vestibular and proprioceptive information48,49, in a process known as path 
integration. This process has a pivotal role in an individual’s ability to successfully maintain 
movement through the environment42,50.  
 
The ability to use environmental landmarks to navigate also relies on the translation of egocentric to 
allocentric information (for example ‘I am 20 meters from the church’ to ‘the supermarket is to the 
left of the church’) and vice versa. For example, when one’s location in an environment has been 
determined, the navigation system calculates subsequent routes on the basis of a combination of 
egocentric and allocentric information. For instance, self-motion, distance travelled, head direction 
during the journey51, and temporal order of observed stimuli are combined across navigation frames. 
This strategic translation between allocentric and egocentric reference frames is a core determinant of 
one’s navigational ability and might be of particular importance for detecting very early signs of 
disorientation by clinical examination.  
 
Thus, egocentric and allocentric navigation strategies integrate for optimal performance in daily 
functioning and are associated with a network of brain regions that operate conjointly but can also be 
dissociated from each other 52. Indeed, successful navigation can be achieved by employing just one 
of these navigation processes at a time. For example, employing only egocentric navigation, it is 
possible to go from one landmark to another without knowing the relationship between landmarks 
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(allocentric information), as the overall path might be stored in a series of visual snapshots or scene 
memories53,54. Similarly, egocentric navigation is also not required for allocentric navigation. When 
walking from one’s house to the garden, the ability to measure bodily distance from landmarks 
(egocentric strategy) might not be necessary if a cognitive representation of the spatial trajectory 
already exists. Such a dissociation is often employed in experimental navigation tests by asking 
participants to remember locations on the basis of direction information while background cues are 
rotated or removed54–56. Evidence also suggests inter-individual differences for navigation preference, 
such that individuals preferentially choose specific strategies or reference frames when attempting to 
solve spatial tasks52. Outside the experimental paradigm, however, the human navigation system 
encourages the natural interaction (or strategic translation) of egocentric and allocentric strategies and, 
therefore, it is important to identify translational impairment in the clinical setting.  
 
[H3] Neural correlates of spatial navigation 
Advances in the field have shown that a large network of brain regions, involving MTL regions 
(hippocampus, entorhinal cortex and parahippocampal cortex57), parietal lobe regions (posterior 
cingulate, precuneus58 and retrosplenial cortex (RSC)59,60), frontal lobe regions61, and subcortical 
structures (caudate nucleus46 and thalamus 62,63) underlie our ability to navigate (Figure 2). 
Electrophysiological recordings in freely moving rodents offered the original insights into spatially 
tuned neurons that independently code for various aspects of navigation such as place location, head 
direction, speed and environmental boundaries. Likewise, in humans these sophisticated cells together 
form the neural architecture that underlies the navigation system.  
Allocentric navigation strategies are thought to be represented by highly selective cell ensembles 
commonly found in the hippocampal CA1 and CA3 regions of the MTL. These so-called ‘place cells’ 
contribute to the formation of cognitive maps of the environment, providing local information about 
one’s location within that environment. Both rodent and human models show that place cells become 
stable and more spatially restricted with repeated exposure to an environment (that is, as one becomes 
more familiar with the surrounding area). On the other hand, large-scale spatial information is 
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provided by grid cells located primarily in the medial entorhinal cortex, which can encode grid-like 
representations of distinct positions in space (self-location) and calculate routes between 
locations41,43,64. Grid cells represent a core component of the neural system that underlies path 
integration, as they also seem to measure ‘distance travelled’ akin to an odometer64,65.  
In addition, head direction cells (which were first identified in the postsubiculum of the rat) encode 
orientation in space and are activated whenever one is facing a certain direction (the reference 
direction 66 . Since their first discovery in rats, these cells have been found in the posterior parietal 
cortex, RSC, dorsal presubiculum, postsubiculum and anterior thalamus in humans [Au: OK?] 67,68. 
Boundary vector cells69 and cells coding specifically for self-motion (path integration)43,50,70, 
complement other spatial representations and together might be used to rapidly form goal-independent 
maps of the environment.  
Previous work suggests that the posterior cingulate region, RSC and precuneus have major roles in the 
integration of egocentric and allocentric spatial information streams71. For example, the rodent 
posterior cingulate receives dense direct hippocampal connections from the subiculum and is thus 
considered an integrative hub for projections from the hippocampus and anterior thalamic nuclei72. 
Interactions between the egocentric parietal and allocentric MTL systems are mediated by the 
RSC51,73–75 as it projects to the parahippocampal gyrus and other areas including the entorhinal cortex, 
presubiculum, thalamus and posterior parietal cortex.76,77 Moreover, the medial prefrontal cortex has 
been shown to receive information from the posterior parietal cortex and the hippocampus and may be 
involved in upstream processing of the spatial information generated 78,79. 
Functional imaging studies in rodents and humans have shown that the RSC is a major contributor to 
navigational performance, especially accurate path integration in darkness80, recognizing permanent 
environmental objects59, binding together multiple cues within the environment71, and encoding and 
storing spatial information72. In healthy individuals, the RSC responds selectively to environmental 
objects with high permanence such as telephone booths or street lights59,81. However, self-reported 
‘poor navigators’ show reduced retrosplenial cortex activation in response to high-permanence 
landmarks and have more difficulty estimating object permanency compared with self-reported ‘good 
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navigators’60. Moreover, the functional connectivity between the RSC and anterior thalamus nuclei is 
reduced in poor navigators60, consistent with the literature from rodent studies63. The ability to 
recognise permanent objects in the environment is a general skill required to make appropriate 
decisions related to navigation, thus emphasising the important role, within the wider posterior 
cingulate region, of the RSC in spatial navigation. Understanding spatial navigation performance in 
healthy individuals is a crucial starting point before inferences can be drawn about initial sites of 
functional abnormality in patients with AD or preclinical individuals. 
 
[H3] Ageing and spatial navigation         
The majority of research on spatial navigation in normal ageing supports a general consensus that 
human and rodent navigational ability, especially allocentric processing,82,83 declines with age18,84,85. 
Reduced resting-state blood flow86, long-term potentiation of rodent synaptic function87, and 
decreased hippocampal volumes in humans88 are some of the mechanisms that underpin this gradual 
decline. Along with these age-related neural changes, deficits in place learning83, perception of self-
motion, 89and retrieval of spatial memories90 have been reported in humans. Based on rodent studies, 
such navigational errors are believed to be a consequence of computational changes within neural 
circuits of the medial prefrontal cortex and CA1 and CA3 regions of the hippocampus91. These age-
related changes give rise to deficits in spatial working memory as well as difficulties maintaining and 
retrieving allocentric representations.91,92 Interestingly, reduced allocentric processing, mostly related 
to spatial memory (that is, encoding and retrieval of route trajectories and environmental maps) is 
suggested to lead to a compensatory shift toward egocentric or path integration navigational 
processes, as they do not rely on memory per se84,93. This idea is consistent with the finding that older 
adults between 60-80 years of age actually outperform younger adults on egocentric94 and allocentric 
distance tasks for example, manually adjusting the length of a line until its length matches the distance 
of a target 95. The preservation of these spatial processes in healthy ageing might therefore have 
important implications for the effective discrimination of age-related and AD-related decline in 
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navigational ability84, and also has implications for navigational rehabilitation strategies for AD in the 
future.  
 
[H1] Spatial navigation as a diagnostic tool  
Early identification — based on navigational difficulties — of individuals who are likely to develop 
AD is currently complicated by the challenges of measuring different features of spatial navigation in 
humans. Reliable tests of spatial navigation that are suitable for clinical settings across centres and 
different patient populations are still in development, as most experimental tests are not feasible for 
clinical evaluation. Validated, simple visuospatial tests such as the widely used Mental Rotation 
Test96 and the Money Road Map test97 have been shown to be poor predictors of navigational 
abilities98,99 and cognitive decline100. Newly developed virtual reality or real-world tests of spatial 
cognition have proven more sensitive in identifying spatial navigation deficits in patient populations. 
In particular, virtual reality testing can be applied as an alternative to real-world reality tests (that are 
difficult to administer with space constraints in clinical settings) to measure navigational abilities in 
younger and older age groups101, patients with MCI and early AD102. These computer-generated 
virtual environments provide tightly controlled testing conditions and also enable manipulation of 
navigational parameters, such as landmark availability and navigation complexity. The adoption of 
tablet computers by clinical services for cognitive testing will make the testing of spatial navigation 
deficits more sophisticated and sensitive in everyday clinical practice. Furthermore, extraction of 
critical features from these virtual reality tests might enable development of further pencil & paper or 
bedside assessments. 
 
[H3] Early AD  
Previous studies using virtual reality techniques have shown that spatial disorientation in patients with 
AD typically includes both egocentric and allocentric impairments linked to widespread 
neurodegeneration in medial temporal, parietal and frontal brain regions17,103–106 (Figure 2). In 
accordance with these findings, both types of navigational strategy have been found to be impaired in 
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early AD dementia, alongside impairments in the translation of both reference frames105 and the 
ability to construct novel scenes from spatial and contextual information, which is dependent on 
posterior parietal regions such as the supramarginal and angular gyrus 106. Virtual reality studies found 
that patients with early AD were unable to store an allocentric viewpoint-independent representation 
and to synchronize this representation with the allocentric viewpoint dependent representation (e.g., 
memorize the position of the plant and retrieve the plant’s position from a different location)17 
probably as a result of reduced hippocampal neuronal density particularly in CA1 and CA3 
subregions107. Egocentric impairments are also present, mainly as a result of hypometabolism and 
structural medial parietal changes, which are signature features of AD108. Surprisingly, these medial 
parietal changes and associated egocentric impairments have been much less investigated in AD, 
despite having potentially much higher specificity for AD pathology. Indeed, retrosplenial (Brodmann 
areas 29 and 30) volumetric changes have been shown to efficiently distinguish AD from FTD, even 
in patients with similar hippocampal atrophy 14,109.  
As noted above, patients with AD also experience difficulty translating between allocentric and 
egocentric reference frames, a function that strongly correlates with RSC and posterior cingulate 
dysfunction and has been shown to distinguish AD from FTD14,105 . Given the role of the RSC in 
integrating different navigational frames, orientation and visual information from the occipital lobes, 
its dysfunction in early AD is in agreement with deficits in translation between allocentric and 
egocentric representations that occur at early clinical stages of the disease and are highly specific to 
underlying AD pathophysiology110. For this reason, the RSC is often considered an initial site of 
functional abnormality in patients with AD or in preclinical individuals. 
 
[H3] Prodromal AD and MCI      
Similar to early AD, patients with MCI often show spatial navigation impairments111. Although the 
exact trajectory from MCI to AD is still under discussion112, a large number of studies show 
functional and structural changes in the MTL and parietal cortex in patients with MCI18,108,113–116. 
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Investigations of egocentric and allocentric memory in individuals with amnestic MCI (aMCI) 
indicate that these patients have substantial volume reductions in the hippocampus, right-sided 
precuneus and inferior parietal cortex, and are severely impaired at learning both allocentric and 
egocentric tasks108. Indeed, path integration in spatial navigation tests is substantially impaired among 
prodromal cohorts and might represent a cognitive marker for AD117. Furthermore, a study employing 
a human real-life version of the Morris water maze [G]  found that patients with AD had problems 
navigating and using both allocentric and egocentric orientation; aMCI groups were more severely 
impaired on allocentric trials111, probably due to the stronger emphasis on memory in these trials118.  
Interestingly, genetic vulnerability interacts with aMCI to influence spatial navigation performance. 
The apolipoprotein E ε4 allele (APOE ε4), which is a known genetic risk factor for AD, has 
high prevalence but low penetrance in the population, with a threefold increased risk of 
developing AD in APOE ε3/ε4 heterozygotes and a tenfold increased risk in APOE ε4/ε4 
homozygotes compared with APOE ε4 non-carriers (see genetics section later, and for more 
details see elsewhere119. On a computerised human analogue of the Morris water maze test (Hidden 
Goal Task), aMCI APOE ε4 homozygous carriers are poorer on all spatial navigation subtasks, 
including allocentric (hippocampus-dependent) and egocentric subtasks, compared with aMCI APOE 
ε4 heterozygous carriers120. 
Despite the strong focus on MTL contributions to navigational deficits in AD, findings suggest an 
increasingly important role for the posterior cingulate cortex and RSC; these areas are affected early 
in the course of AD121 and in patients at early MCI stages122,123, especially those who then progress to 
AD116,122,124,125. However, questions around the contributions of the RSC and associated posterior 
cingulate areas to spatial navigation deficits in early AD remain unanswered. In addition, whether 
changes in the RSC reflect a compensatory mechanism that occurs as a result of early AD pathology 
in the transentorhinal cortex and hippocampus at the microscopic level remains unclear. Such a 
finding would not be surprising, however, as the entorhinal cortex has a strong anatomical connection 
with the RSC126. 
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[H3] Preclinical AD           
Although evidence is emerging that spatial navigation is impaired in early AD and MCI, its integrity 
in preclinical populations is less well understood. Various attempts have been made to determine 
spatial neural and cognitive biomarkers in individuals as young as 45 years who have an elevated 
sporadic or genetic risk of progressing to AD 127. Preclinical investigations have reported functional 
MRI abnormalities in the resting-state default mode network, including reduced functional 
connectivity in posterior cingulate cortices and precuneus regions128,129, both of which underlie 
egocentric ability and egocentric to allocentric translation. 
Studies in sporadic preclinical AD have partially relied on CSF Aβ levels. For example, a study from 
201620 investigated spatial navigation as a marker for AD, using two non-immersive desktop virtual 
maze environments for allocentric and egocentric conditions. Individuals were considered preclinical 
if they had low CSF Aβ levels (<500 pg/ml)130, with no cognitive deficits. Selective deficits in 
allocentric strategy among preclinical individuals were reported relative to individuals with a normal 
Aβ level in the CSF (>500 pg/ml). Despite allocentric acquisition impairments, the preclinical group 
retained sufficient information to solve the wayfinding task. However, the exact contribution of 
decreased CSF Aβ levels to impairment of allocentric and egocentric processing is uncertain, as 
increasing evidence suggests that the tau protein has a critical role in the generation of cognitive 
deficits 131,132. Experiments in aged transgenic mice expressing human tau  suggest that the interaction 
of reduced excitatory grid cell firing in the dorsal medial entorhinal cortex and increased activity of 
inhibitory cells in response to enhanced theta oscillations results in the spatial memory deficits seen in 
early AD16. This finding links the destabilization of grid cell fields (which code for route trajectories 
and update spatial information) with the earliest stage of tau pathology. The significance of this 
finding in relation to preclinical AD, however, remains to be determined (see Figure 3) 
In human studies, preclinical individuals carrying mutations in the presenilin 1 and amyloid precursor 
protein genes show entorhinal and posterior cingulate cortical thickness changes up to 8 years before 
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disease onset133. However, to our knowledge, spatial navigational ability has not been investigated in 
these particular preclinical patients. These predictive MRI findings underline the strong need for 
longitudinal investigations to examine the sensitivity of cortical thickness changes as neural markers 
for AD and the manifestation of spatial navigation disparities for predicting later conversion to MCI 
and early AD.  
Most navigation studies in cohorts of patients with genetic risk factors for AD have been conducted 
with APOE-genotyped individuals. The association between the APOE ε4 allele and AD risk has 
spurred a growing number of studies investigating the cognitive and neurophysiological effect of 
APOE ε4 in younger 18-24 year olds,134,135 middle-aged 40-60 year olds 136–139 and elderly 60-90 year 
old individuals 140 adults, also in relation to spatial performance and hippocampal volume120. 
 
A study examined a possible link between APOE ε4 and spatial navigation in genetically at-risk 
young healthy adults. Reduced grid-cell-like representation was observed in APOE ε3/ε4 carriers 
compared with APOE ε3/ε3 individuals, suggesting functional (but no structural) differences between 
young APOE ε4 carriers and non-carriers. Grid-cell representations were temporally unstable in young 
adult carriers as functional connectivity between the right entorhinal cortex and hippocampus was 
impaired, leading to a behavioural preference to navigate along the border of the virtual environment. 
The authors proposed a potential compensatory mechanism of the hippocampus due to neuronal loss 
in the entorhinal cortex and reduced grid-cell representations which enabled young adult carriers to 
navigate successfully and complete the task 21,141. Clearly, preclinical cohorts are of great interest for 
future navigation research in AD pathophysiology, not only for individuals at genetic risk, but also for 
sporadic high-risk groups. 
 
An alternative approach is to investigate preclinical cognitive forms of AD via healthy elderly 
participants who have significant memory concerns (SMCs) [G] but do not reach cut-offs for 
objective memory impairment on standard neuropsychological measures. Such SMCs are a potential 
harbinger of AD pathology142. However, it should be emphasised that no gold standard tool currently 
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exists to identify SMCs, and no threshold values to suggest clinically relevant SMCs have been 
established. Unsurprisingly, few studies have explored spatial navigation in SMC cohorts111. 
However, evidence does suggest a positive association between amyloid pathology, genetic risk of 
AD, entorhinal cortex integrity and SMCs143,144, which might ignite new interest in whether SMCs and 
navigational difficulties are comorbid among genetically at-risk cohorts.  
 
[H1] Conclusions 
This review underscores the presence of spatial navigation impairments in early AD and its prodromal 
and preclinical forms. The evidence reviewed clearly highlights the great potential of spatial navigation 
and orientation deficits as diagnostic measures and predictors of incipient AD pathophysiology. The 
findings should not be surprising as MTL and posterior parietal regions, which constitute the core 
network for navigation, are highly susceptible to AD pathophysiology even in the prodromal and 
preclinical stages of the disease. An urgent need exists to revisit the notion that episodic memory should 
be the gold standard for early AD diagnosis and outcome intervention studies. Specifically, the literature 
indicates that spatial navigation deficits can identify individuals at risk of developing AD, which has 
obvious implications for clinical practice. For example, routine assessment of spatial navigation 
complaints should be considered a priority in memory clinics38. If subjective complaints are present, 
particularly when accompanied by behavioural symptoms that manifest as everyday difficulties 
navigating previously familiar routes and/or using public transport, the patient should be considered at 
high risk of developing AD. Identification of incipient AD might provide an earlier opportunity to begin 
potentially disease-modifying treatment before more substantial and deadly brain changes occur. 
Spatial navigation parameters could also have an important role in animal to human translational 
research. Drug development for AD has been hampered by the failure to replicate success in animal 
models (tested with spatial navigation measures) in phase II or III clinical trials. A 3-month open-
label study has shown that a computerized human analogue of the Morris water maze has the potential 
to measure the effects of donepezil in mild AD145. Subsequent research has shown that the disruptive 
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effect of scopolamine on place navigation can be reverted by donepezil, a finding that was 
demonstrated using both rodent and human versions of the Morris water maze146.  
The past few years have seen a considerable shift in interest towards patients with prodromal AD, and 
some of the conventional neuropsychological tests for AD might be subject to a ceiling effect in these 
patients. Only a few subtests of current measures have the potential to show differences in the effects 
of drugs and placebo in patients with prodromal AD or MCI. Therefore, spatial navigation, as a 
sensitive and specific marker of AD, presents a window of opportunity in these patients. Furthermore, 
in the era of cross-cultural clinical trials, tests that are independent of language and culture (such as 
those for spatial navigation) facilitate comparison across research sites. 
From a social care perspective, the findings presented offer important information for dementia care 
organisations. Disorientation leads to patients getting lost in everyday environments, resulting in 
distress for patients and family members and often the involvement of the emergency services and in 
extreme cases leading to death from exposure. Thus, the identification of individuals with spatial 
navigation deficits might enable better safeguarding to be put in place for those individuals. 
Despite clear clinical applications of the research, spatial navigation has several limitations as a 
diagnostic tool for AD. One major question is whether spatial deficits occur before episodic memory 
deficits or whether both deficits manifest concurrently in humans. Navigation and orientation tests can 
only be considered superior to episodic memory tests if they are shown to be more sensitive and 
specific for AD pathology. However, given that the normal ageing process will probably give rise to 
complaints around memory of past events, as opposed to ability to navigate and orientate oneself in 
space, disorientation should be further investigated as a potentially more valuable (specific) marker to 
distinguish pathological ageing from normal ageing. This rationale leads to a pressing need to develop 
a standardized and validated diagnostic spatial test battery that does not rely on topographical 
memory. These tests might also be used as a clinical diagnostic tool and outcome marker in upcoming 
treatment efficacy trials, as current navigation tools are limited and not standardized across research 
centres. Given the multifactorial nature of the navigation system, such a battery of tests should 
consider not only mnemonic processes, but also higher mental functions mediated by the frontal lobe 
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such as planning, motivation and maintenance of spatial representations that influence navigational 
ability. This approach is especially important when considering a differential diagnosis, for example, 
between AD and FTD syndromes.  
Importantly, spatial navigation studies in AD might be limited in their comparability, as many of the 
studies predate the publication of robust diagnostic criteria for AD7. As a result, the potential for 
mixed or other forms of dementia to confound an established cohort of patients with AD cannot be 
ruled out. It is also difficult to say with certainty that cut-off points for disease staging (preclinical, 
early MCI, late MCI) are consistent across studies published before the 2014 guidelines7. In addition, 
heterogeneity in the definition of patient cohorts and differences in spatial navigation paradigms and 
testing procedures have created inconsistencies across studies.  
The current lack of epidemiological data from healthy populations for spatial navigation is a further 
obstacle. Inter-individual differences in spatial navigation remain elusive, with no population-level 
data available to rectify conflicting ideas around, for example, sex differences in navigational 
abilities. One notable exception is the launch of Sea Hero Quest (http://www.seaheroquest.com), an 
online mobile game to measure spatial navigation (Box 1). To date (April 2018), Sea Hero Quest has 
been played by over 3.7 million people, in 193 countries between the ages of 19 and 95 years132. 
Initial results from Sea Hero Quest show that not only age but also gender and cultural background 
have a substantial effect on navigation behaviour, which clearly needs to be investigated further147. 
There is considerable scope to use the data from the game to create the first population benchmarks 
for healthy navigation abilities across ages, gender and countries. Benchmark scores will allow us to 
develop easy-to-administer, sensitive spatial navigation tools validated against benchmark population 
data and also to relate it to real-life navigation problems that patients encounter. Already, navigational 
pattern changes, in preclinical groups defined as genetically-at risk of AD, have been uncovered on 
Sea Hero Quest. This demonstrates the game’s utility to detect cognitive changes that precede the 
expected onset of AD Taken together, the presented evidence highlights the enormous potential of 
spatial navigation for AD diagnosis, which in turn could have a major impact on clinicians, patients 
and their families. 
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Key points 
 Episodic memory has limited utility as a diagnostic and outcome measure for preclinical AD 
 Spatial navigation deficits have the potential to detect underlying pathophysiology in 
preclinical AD  
 The brain areas affected earliest by AD pathophysiology are key nodes in the spatial 
navigation network 
 Genetically at-risk individuals show altered spatial navigation patterns before any episodic 
memory symptom onset  
 Spatial navigation emerges as a potential cost effective cognitive biomarker to detect AD in 
the preclinical stages, which has significant implications for future diagnostics and treatment 
approaches 
 Future spatial navigation benchmarks and standardisation of spatial navigation tests are 
needed to realise this goal 
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Box 1 | Sea Hero Quest 
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Sea Hero Quest (SHQ) is a mobile app-based cognitive task that enables the collection of spatial 
navigation data on a population level. SHQ has been downloaded by 3.7 million people in 193 
different countries worldwide. As people advance in the game, they face challenges in different 
navigation domains, including visuospatial skills, path integration, spatial short-term memory and 
allocentric and /or egocentric navigational strategy.  
Game performance can be divided into two main domains: wayfinding and egocentric path 
integration. In wayfinding levels, players are initially presented with a map indicating start location 
and the location of several checkpoints to find in a set order. The two variables of interest are 
trajectory distance and time taken to complete each level. In path integration levels, participants 
navigate along a river with bends to find a flare gun and then choose the correct direction back to the 
starting point from a choice of three options. Depending on their accuracy, players receive one, two or 
three stars. The game also controls for video gaming proficiency, which might otherwise bias 
performance by giving players familiar with similar games an advantage.  
Current preliminary findings for the population-level navigation data can be found here: 
https://www.biorxiv.org/content/early/2018/01/21/188870 
 
Glossary  
Allocentric Navigation Allocentric strategies are based on the navigator’s perception of landmark 
positions relative to other landmarks  
Egocentric Navigation Egocentric self-centred navigation frames encode spatial information from 
the viewpoint of the navigator 
Episodic memory Episodic memory refers to our memory of events represented by aspects of the 
past not present in other memories, such as the time, place, or social context. 
Mild Cognitive Impairment Mild cognitive impairment (MCI) is a prodromal or intermediate stage 
between the expected cognitive decline of normal aging and the more-serious decline of dementia.  
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Morris water maze: The Morris water maze is a test of spatial learning examining rodent ability to 
navigation from different starting locations around an open swimming arena to location a submerged 
escape platform using only distal cues. For more information see elsewhere148 
Subjective Cognitive Decline: Subjective Cognitive Decline (SCD) refers to a self-experienced 
persistent decline in cognitive abilities in comparison with a prior normal status and occurs in the 
absence of objective impairment on standardised neuropsychological tests 
 
